Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegerthropoietin
- Development stage
- Phase 2
- Lead developer
- Sciprogen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Pegerythropoietin (RD01) is a pegylated form of erythropoietin, designed as an agonist of the erythropoietin (EPO) receptor. It stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production. The drug is being developed primarily for the treatment of anemia, including anemia associated with chronic renal failure and chemotherapy-induced anemia. Its extended half-life due to pegylation allows for less frequent dosing compared to conventional erythropoiesis-stimulating agents. The primary developer is Shenzhen Sciprogen Bio-Pharmaceutical. Clinical trials have reached Phase 2 for indications such as anemia in chronic renal failure patients on hemodialysis and chemotherapy-induced anemia in non-metastatic breast cancer patients[1][2].
- Brand names
- Pegerythropoietin
- Other names
- Pegylated erythropoietin
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on pegerthropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegerthropoietin.